<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bacterial arthritis: Treatment and outcome in infants and children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bacterial arthritis: Treatment and outcome in infants and children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bacterial arthritis: Treatment and outcome in infants and children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul A Krogstad, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William A Phillips, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Suzanne C Li, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Infections of the joints (known as septic arthritis, pyogenic arthritis, suppurative arthritis, purulent arthritis, or pyarthrosis) may be caused by bacteria, fungi, mycobacteria, and viruses. The term "septic arthritis" usually refers to bacterial arthritis or fungal arthritis, but bacterial joint infections are most common [<a href="#rid1">1,2</a>].</p><p>The treatment and outcome of bacterial arthritis in infants and children will be reviewed here. The epidemiology, pathogenesis, microbiology, clinical features, and diagnosis of bacterial arthritis in infants and children; acute hematogenous osteomyelitis in infants and children; and the treatment of arthritis caused by Lyme disease are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6032.html" rel="external">"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6030.html" rel="external">"Bacterial arthritis: Clinical features and diagnosis in infants and children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6063.html" rel="external">"Hematogenous osteomyelitis in children: Epidemiology, pathogenesis, and microbiology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6064.html" rel="external">"Hematogenous osteomyelitis in children: Clinical features and complications"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6067.html" rel="external">"Hematogenous osteomyelitis in children: Evaluation and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5958.html" rel="external">"Hematogenous osteomyelitis in children: Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7896.html" rel="external">"Treatment of Lyme disease", section on 'Arthritis'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Bacterial arthritis requires prompt recognition and management. Delays in treatment are associated with long-term damage to bones and joints, particularly when the hip or shoulder joint is involved. (See <a class="local">'Outcome'</a> below.)</p><p class="headingAnchor" id="H2914418296"><span class="h2">Goals</span><span class="headingEndMark"> — </span>The goals of treatment include sterilization and decompression of the joint space and removal of inflammatory debris to relieve pain and prevent deformity or functional sequelae [<a href="#rid1">1,3</a>]. Drainage of joint fluid and antimicrobial therapy are the cornerstones of therapy.</p><p class="headingAnchor" id="H455912253"><span class="h2">Indications for consultation</span><span class="headingEndMark"> — </span>Children with documented or suspected bacterial arthritis should be managed in conjunction with an orthopedic surgeon who is experienced in treating children. Aspiration of the joint should occur as soon as possible when bacterial arthritis is suspected. Joint aspiration provides synovial fluid for analysis and culture and decompresses the joint. Indications for definitive drainage may include bacterial arthritis of the hip and shoulder, failure to improve after 48 hours of antimicrobial therapy, and persistently positive synovial cultures (if obtained). (See  <a class="medical medical_review" href="/d/html/6030.html" rel="external">"Bacterial arthritis: Clinical features and diagnosis in infants and children", section on 'Synovial fluid'</a> and <a class="local">'Drainage'</a> below.)</p><p>Given the frequency of contiguous osteomyelitis, antibiotic-resistant pathogens, and culture-negative cases, consultation with an expert in infectious diseases is also recommended, particularly for children with [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative infection</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic joint infection</p><p class="bulletIndent1"><span class="glyph">●</span>Penetrating injury (may be associated with unusual pathogens; usually is more complex than hematogenous arthritis)</p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate response to therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Prosthetic joint</p><p class="bulletIndent1"><span class="glyph">●</span>Unusual pathogens (eg, <em>Pasteurella multocida</em>, <em>Cutibacterium acnes </em>[in children with prosthetic joints],<em> </em>fungal pathogens)</p><p class="bulletIndent1"><span class="glyph">●</span>Antimicrobial allergy</p><p class="bulletIndent1"><span class="glyph">●</span>Immunodeficiency or on immunosuppressive treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis or hemodynamic instability</p><p></p><p class="headingAnchor" id="H7"><span class="h1">DRAINAGE</span><span class="headingEndMark"> — </span>Joint drainage is a cornerstone of treatment for bacterial arthritis [<a href="#rid5">5-8</a>]. At the time of presentation, joint infections are essentially closed abscesses. Drainage and lavage are necessary to decompress the joint space and to remove inflammatory debris to preserve synovium and collagen matrix [<a href="#rid5">5,9</a>].</p><p class="headingAnchor" id="H656740695"><span class="h2">Drainage procedures</span><span class="headingEndMark"> — </span>Drainage can be accomplished through arthrotomy, arthroscopy, or needle aspiration (single or multiple) [<a href="#rid1">1,10-13</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arthrotomy</strong> – Arthrotomy facilitates thorough debridement of infected tissue, breakdown of loculations, and irrigation of the joint space [<a href="#rid9">9,14,15</a>]. However, arthrotomy requires general anesthesia and is more invasive than arthroscopy or needle aspiration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arthroscopy</strong> – Arthroscopy with irrigation and debridement is an alternative to arthrotomy for surgical drainage of bacterial arthritis in uncomplicated cases. Arthroscopy is less invasive than arthrotomy, and good outcomes have been reported in young children [<a href="#rid16">16-19</a>]. However, arthroscopic views may be limited, leading to inadequate irrigation or debridement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Needle aspiration </strong>– Aspiration has minimal morbidity and, in the older child, may not require general anesthesia [<a href="#rid15">15</a>]. However, it may provide less satisfactory drainage than arthrotomy or arthroscopy. If the joint is thoroughly drained during diagnostic aspiration, a single aspiration may suffice [<a href="#rid20">20</a>]. Repeat aspiration may be necessary if fluid reaccumulates. However, young children may be difficult to assess and distressed by repeated procedures.</p><p></p><p class="bulletIndent1">In observational studies in adult patients, the outcome of bacterial arthritis in patients treated with repeated needle aspiration was better than in those treated with surgical drainage [<a href="#rid13">13,21</a>]. Good outcome was defined by restoration of joint function with minimal or no residual pain.</p><p></p><p class="headingAnchor" id="H4192087563"><span class="h2">Factors that affect choice of drainage procedure</span><span class="headingEndMark"> — </span>Decisions regarding the optimal drainage procedure should be individualized according to the site and extent of involvement, duration of symptoms, the suspected organism, and other clinical features [<a href="#rid1">1,9</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hip or shoulder involvement </strong>– For children with bacterial arthritis of the hip or shoulder, we prefer open surgical drainage (arthrotomy) to arthroscopy or needle drainage.</p><p></p><p class="bulletIndent1">Delayed or inadequate drainage increases the likelihood of adverse outcome. Increased intra-articular pressure can compromise the blood supply to the femoral head, resulting in avascular necrosis [<a href="#rid22">22,23</a>]. Given the potential for long-term complications and adjacent osteomyelitis in children with bacterial arthritis of the hip or shoulder [<a href="#rid22">22-24</a>], open surgical drainage is the optimal approach for thorough debridement, breakdown of loculations, and irrigation of the joint space. (See <a class="local">'Drainage procedures'</a> above.)</p><p></p><p class="bulletIndent1">Although there are reports of successful treatment of bacterial arthritis of the hip or shoulder with arthroscopic drainage or needle aspiration, these reports generally involved older children, children with methicillin-susceptible <em>Staphylococcus aureus</em>, pathogens other than<em> S. aureus</em>, or brief duration of symptoms before presentation [<a href="#rid15">15,19,25-33</a>]. Pending additional high-quality studies, we continue to prefer open surgical drainage in children with bacterial arthritis of the hip or shoulder. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other joints</strong> – For joints other than the hip and shoulder, arthroscopy and needle aspiration are alternatives to arthrotomy [<a href="#rid12">12,20,21,34</a>]. If the joint is thoroughly drained during diagnostic aspiration, a single aspiration may suffice [<a href="#rid20">20</a>]. Repeat aspiration may be necessary if fluid reaccumulates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Penetrating trauma</strong> – For children with bacterial arthritis and penetrating trauma, arthrotomy permits thorough debridement and removal of any radiolucent foreign bodies, if present [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Concomitant osteomyelitis or large amount of debris or loculations </strong>– For children with bacterial arthritis and concomitant osteomyelitis, subperiosteal abscess, or large amount of debris or loculations, arthrotomy may be preferred because it permits better anatomic evaluation (eg, of the femoral neck in hip joint arthritis) and thorough debridement in a single procedure [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gonococcal arthritis</strong> – Gonococcal arthritis seldom involves hip or shoulder joints and usually resolves without surgical drainage [<a href="#rid36">36</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h1">ANTIBIOTIC THERAPY</span></p><p class="headingAnchor" id="H1485741458"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Antibiotic therapy is necessary to sterilize the joint fluid. Empiric antimicrobial therapy should be initiated as soon as possible after blood and synovial fluid cultures have been obtained in infants and children with characteristic clinical and laboratory features of bacterial arthritis [<a href="#rid8">8,10,37</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Characteristic clinical features include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Newborns and young infants – Clinical manifestations of sepsis (eg, irritability, poor feeding), pseudoparalysis, evidence of discomfort when being handled, or fever without a focus</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Older infants and children – Fever and monoarticular pain, swelling, and limited range of motion</p><p></p><p class="bulletIndent2">(See  <a class="medical medical_review" href="/d/html/6030.html" rel="external">"Bacterial arthritis: Clinical features and diagnosis in infants and children", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Characteristic laboratory features include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elevated peripheral white blood cell (WBC) count, C-reactive protein (CRP), and /or erythrocyte sedimentation rate (ESR)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elevated synovial fluid WBC count (&gt;20,000 cells/microL) with a predominance of neutrophils</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Organism identified on Gram stain of synovial fluid</p><p></p><p class="bulletIndent2">(See  <a class="medical medical_review" href="/d/html/6030.html" rel="external">"Bacterial arthritis: Clinical features and diagnosis in infants and children", section on 'Laboratory evaluation'</a>.)</p><p></p><p>The differential diagnosis also must be carefully considered to identify disorders with clinical features similar to bacterial arthritis that do not require joint drainage or prolonged antibiotic therapy (eg, transient synovitis, Lyme arthritis, juvenile idiopathic arthritis). (See  <a class="medical medical_review" href="/d/html/6030.html" rel="external">"Bacterial arthritis: Clinical features and diagnosis in infants and children", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H480586431"><span class="h2">Empiric parenteral therapy</span></p><p class="headingAnchor" id="H1519426724"><span class="h3">Factors in choice of regimen</span><span class="headingEndMark"> — </span>Coverage for <em>S. aureus</em> (the most common cause of bacterial arthritis) should be included in the empiric regimen for children of all ages [<a href="#rid8">8</a>]. Coverage for additional pathogens may be necessary based upon the child's age  (<a class="graphic graphic_table graphicRef53150" href="/d/graphic/53150.html" rel="external">table 1</a>), particular clinical circumstances  (<a class="graphic graphic_table graphicRef75192" href="/d/graphic/75192.html" rel="external">table 2</a>), and Gram stain  (<a class="graphic graphic_table graphicRef112013" href="/d/graphic/112013.html" rel="external">table 3</a>) [<a href="#rid1">1,3,35,38</a>]. Empiric therapy can be altered when the susceptibility pattern of the causative bacterium is known.</p><p>Few randomized controlled studies have evaluated antibiotic regimens for bacterial arthritis. All antibiotics that have been studied readily enter the joint fluid after systemic administration; intra-articular injection of antibiotics is unnecessary and may be painful. The joint fluid concentration for most penicillins and cephalosporins averages 30 percent of the serum concentration at the time of peak serum concentration, and, because of slow efflux from the joint fluid, may exceed serum concentration immediately before the next dose [<a href="#rid39">39-43</a>].</p><p class="headingAnchor" id="H13"><span class="h3">Children younger than three months</span><span class="headingEndMark"> — </span>Empiric therapy for bacterial arthritis in infants &lt;3 months of age should be directed against <em>Staphylococcus</em>, group B <em>Streptococcus </em>(GBS), and gram-negative bacilli  (<a class="graphic graphic_table graphicRef53150" href="/d/graphic/53150.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/6032.html" rel="external">"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children", section on 'Microbiology'</a>.)</p><p>For empiric parenteral therapy in children younger than three months with suspected bacterial arthritis, we generally provide combination therapy with an antistaphylococcal agent and either a third-generation cephalosporin or <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a>  (<a class="graphic graphic_table graphicRef51833" href="/d/graphic/51833.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef129344" href="/d/graphic/129344.html" rel="external">table 5</a>). Appropriate regimens vary with the clinical presentation and risk factors for methicillin-resistant <em>S. aureus </em>(MRSA) or coagulase-negative staphylococci  (<a class="graphic graphic_algorithm graphicRef120251" href="/d/graphic/120251.html" rel="external">algorithm 1</a>).</p><p>For infants with allergy or intolerance to cephalosporins (very uncommon in this age group), we suggest consultation with an expert in pediatric infectious diseases.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Signs of sepsis </strong>– For infants &lt;3 months of age with signs of sepsis (eg, tachycardia, poor perfusion, hypotension), we provide empiric therapy with either  (<a class="graphic graphic_algorithm graphicRef120251" href="/d/graphic/120251.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a> <strong>plus</strong> <a class="drug drug_pediatric" data-topicid="12626" href="/d/drug information/12626.html" rel="external">nafcillin</a> or <a class="drug drug_pediatric" data-topicid="12663" href="/d/drug information/12663.html" rel="external">oxacillin</a> <strong>plus</strong> one of the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">Cefotaxime</a> (preferred if available)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">Ceftazidime</a></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">Ceftriaxone</a> (for infants who are not receiving intravenous [IV] calcium-containing solutions [<a href="#rid44">44</a>])</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a> <strong>plus </strong><a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a> – Although cefepime provides activity against methicillin-susceptible <em>S. aureus (</em>MSSA), some experts would add <a class="drug drug_pediatric" data-topicid="12626" href="/d/drug information/12626.html" rel="external">nafcillin</a> or <a class="drug drug_pediatric" data-topicid="12663" href="/d/drug information/12663.html" rel="external">oxacillin</a> for optimal activity against MSSA in infants with signs of sepsis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No signs of sepsis but with risk factors for MRSA or coagulase-negative staphylococci </strong>– Risk factors for MRSA include care in the intensive care unit for &gt;1 week; mother with, or suspected to have, infection or colonization with community-acquired <em>S. aureus</em>; and increased prevalence of MRSA at the admitting institution (eg, ≥10 percent of <em>S. aureus</em> isolates are methicillin resistant). Prematurity and prolonged or recurrent bacteremia with coagulase-negative staphylococci despite antibiotic therapy are the primary risk factors identified for bacterial arthritis with these organisms in neonates [<a href="#rid45">45-47</a>].</p><p></p><p class="bulletIndent1">For infants without signs of sepsis but with risk factors for MRSA or coagulase-negative staphylococci, we provide empiric therapy with  (<a class="graphic graphic_algorithm graphicRef120251" href="/d/graphic/120251.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a> <strong>plus</strong> one of the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">Cefotaxime</a> (preferred if available)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">Ceftazidime</a></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">Ceftriaxone</a> (for infants who are not receiving IV calcium-containing solutions [<a href="#rid44">44</a>])</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">Cefepime</a> (a fourth-generation cephalosporin)</p><p></p><p class="bulletIndent2">At some institutions, <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> is used as an alternative to <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> if &lt;10 percent of <em>S. aureus</em> isolates are clindamycin resistant and the infant has localized infection with no signs of sepsis. Other experts may use a different threshold for clindamycin resistance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No signs of sepsis and no risk factors for MRSA or coagulase-negative staphylococci</strong> – For infants without signs of sepsis and without risk factors for MRSA or coagulase-negative staphylococci, appropriate regimens include either:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Combination therapy with  (<a class="graphic graphic_algorithm graphicRef120251" href="/d/graphic/120251.html" rel="external">algorithm 1</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>One of the following antistaphylococcal agents: <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>, <a class="drug drug_pediatric" data-topicid="12626" href="/d/drug information/12626.html" rel="external">nafcillin</a>, or <a class="drug drug_pediatric" data-topicid="12663" href="/d/drug information/12663.html" rel="external">oxacillin</a>; <strong>plus</strong></p><p class="bulletIndent3"><span class="glyph">-</span>One of the following gram-negative agents: <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a> (preferred if available), <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a>, or <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a> (for infants who are not receiving IV calcium-containing solutions [<a href="#rid44">44</a>])</p><p></p><p class="bulletIndent2"><a class="drug drug_pediatric" data-topicid="13124" href="/d/drug information/13124.html" rel="external">Cefazolin</a> is an alternative antistaphylococcal agent for infants age one to three months in whom central nervous system infection has been excluded.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monotherapy with <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a> (a fourth-generation cephalosporin)</p><p></p><p class="bulletIndent2">Although <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a> provides activity against MSSA, some experts would add <a class="drug drug_pediatric" data-topicid="12626" href="/d/drug information/12626.html" rel="external">nafcillin</a> or <a class="drug drug_pediatric" data-topicid="12663" href="/d/drug information/12663.html" rel="external">oxacillin</a> for additional activity against MSSA.</p><p></p><p class="headingAnchor" id="H14"><span class="h3">Children three months and older</span><span class="headingEndMark"> — </span>Empiric therapy for bacterial arthritis in children ≥3 months should be directed toward <em>S. aureus</em> and other gram-positive organisms (eg, group A streptococci, <em>Streptococcus pneumoniae</em>)  (<a class="graphic graphic_table graphicRef53150" href="/d/graphic/53150.html" rel="external">table 1</a>) [<a href="#rid3">3,48,49</a>]. Additional coverage for other pathogens (eg, <em>Kingella kingae</em>, <em>Haemophilus influenzae</em>, <em>N. gonorrhoeae</em>,<em> Salmonella spp</em>) may be necessary in select populations  (<a class="graphic graphic_table graphicRef75192" href="/d/graphic/75192.html" rel="external">table 2</a>). (See <a class="local">'Additional coverage for other pathogens'</a> below.)</p><p class="headingAnchor" id="H1556972432"><span class="h4">Children with hemodynamic instability</span><span class="headingEndMark"> — </span>For severely ill children (eg, those with hemodynamic instability) who are ≥3 months of age, we suggest empiric combination therapy with either of the following combinations  (<a class="graphic graphic_table graphicRef112013" href="/d/graphic/112013.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a> plus <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a> plus one of the following: <a class="drug drug_pediatric" data-topicid="12626" href="/d/drug information/12626.html" rel="external">nafcillin</a>, <a class="drug drug_pediatric" data-topicid="12663" href="/d/drug information/12663.html" rel="external">oxacillin</a>, or <a class="drug drug_pediatric" data-topicid="13124" href="/d/drug information/13124.html" rel="external">cefazolin</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a> plus <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a></p><p></p><p>This combination therapy broadly covers the most likely pathogens to cause septic arthritis complicated by septic shock (MRSA, MSSA, and <em>Neisseria meningitidis</em>). <a class="drug drug_pediatric" data-topicid="12626" href="/d/drug information/12626.html" rel="external">Nafcillin</a>, <a class="drug drug_pediatric" data-topicid="12663" href="/d/drug information/12663.html" rel="external">oxacillin</a>, or <a class="drug drug_pediatric" data-topicid="13124" href="/d/drug information/13124.html" rel="external">cefazolin</a> are superior to <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> for treatment of serious MSSA infections. <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">Ceftriaxone</a> or <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a> provide activity against <em>N. meningitidis</em>.</p><p>We provide empiric antimicrobial therapy for other pathogens as indicated. For children with septic arthritis and hemodynamic instability who are unable to tolerate penicillin and cephalosporin antibiotics, we use <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> in combination with a carbapenem or fluoroquinolone until gram-negative bacteremia is excluded. (See <a class="local">'Additional coverage for other pathogens'</a> below.)</p><p class="headingAnchor" id="H110093695"><span class="h4">Children who are hemodynamically stable</span><span class="headingEndMark"> — </span>Agents that provide coverage for <em>S. aureus</em> and other gram-positive pathogens in children who are hemodynamically stable include <a class="drug drug_pediatric" data-topicid="13124" href="/d/drug information/13124.html" rel="external">cefazolin</a>, <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a>, <a class="drug drug_pediatric" data-topicid="12626" href="/d/drug information/12626.html" rel="external">nafcillin</a>/<a class="drug drug_pediatric" data-topicid="12663" href="/d/drug information/12663.html" rel="external">oxacillin</a>, and <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>. The agent of choice depends on the severity of illness, local prevalence of community-associated MRSA (CA-MRSA), the susceptibility of CA-MRSA isolates to clindamycin, and suspicion for other pathogens  (<a class="graphic graphic_table graphicRef112013" href="/d/graphic/112013.html" rel="external">table 3</a>) [<a href="#rid2">2,8,50,51</a>]. Initial antimicrobial therapy for bacterial arthritis is usually administered parenterally. Drug doses are provided in the table  (<a class="graphic graphic_table graphicRef51833" href="/d/graphic/51833.html" rel="external">table 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>For hemodynamically stable children, we suggest <a class="drug drug_pediatric" data-topicid="13124" href="/d/drug information/13124.html" rel="external">cefazolin</a>, <a class="drug drug_pediatric" data-topicid="12626" href="/d/drug information/12626.html" rel="external">nafcillin</a>, or <a class="drug drug_pediatric" data-topicid="12663" href="/d/drug information/12663.html" rel="external">oxacillin</a> if &lt;10 percent of community <em>S. aureus</em> isolates are methicillin-resistant. Cefazolin also provides coverage for <em>K. kingae</em>. For children who are unable to tolerate penicillin and cephalosporin antibiotics, we suggest <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> if &lt;10 percent of <em>S. aureus</em> isolates are clindamycin resistant. Other experts may use different thresholds for methicillin or clindamycin resistance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For hemodynamically stable children, we suggest either <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> or <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> if ≥10 percent of community <em>S. aureus</em> isolates are methicillin-resistant [<a href="#rid2">2,8,50</a>]. Other experts may use a different threshold for methicillin-resistance.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> for children who have underlying frequent contact with the health care system or who were hospitalized in the past six months because these children may have an increased risk of <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> resistance.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> when ≥10 percent of <em>S. aureus </em>isolates in the community are resistant to <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> (constitutive and inducible). Other experts may use a different threshold for clindamycin resistance. Vancomycin also provides coverage for penicillin-nonsusceptible <em>S. pneumoniae</em>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> when &lt;10 percent of <em>S. aureus</em> isolates in the community are resistant to clindamycin. Clindamycin also covers many penicillin-resistant <em>S. pneumoniae</em> (although a large proportion of serotype 19A isolates are resistant to multiple drugs, including clindamycin).</p><p></p><p>Alternatives to <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> or <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> when MRSA is a concern include <a class="drug drug_pediatric" data-topicid="12555" href="/d/drug information/12555.html" rel="external">linezolid</a> or <a class="drug drug_pediatric" data-topicid="13009" href="/d/drug information/13009.html" rel="external">daptomycin</a> (if the child is ≥1 year of age and has no concomitant pulmonary involvement) [<a href="#rid8">8,50,52</a>]. <a class="drug drug_pediatric" data-topicid="109476" href="/d/drug information/109476.html" rel="external">Ceftaroline</a> is active against many pathogens that cause septic arthritis in children and is under investigation for use in septic arthritis and osteomyelitis in children, but data are limited [<a href="#rid53">53,54</a>].</p><p>In the only study comparing antimicrobial agents for osteoarticular infections, outcomes were similar among 169 Finnish children with culture-proven acute osteoarticular infections who were treated with <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> versus first-generation cephalosporins [<a href="#rid55">55</a>]. In this study, nearly all cases resulted from infection with MSSA (84 percent), <em>S. pyogenes</em> (9 percent), or <em>S. pneumoniae</em> (5 percent).</p><p class="headingAnchor" id="H3932521055"><span class="h4">Additional coverage for other pathogens</span><span class="headingEndMark"> — </span>It may be necessary to <strong>add</strong> empiric coverage for pathogens other than <em>S. aureus</em> and other gram-positives if clinical or laboratory features suggest a specific pathogen  (<a class="graphic graphic_table graphicRef75192" href="/d/graphic/75192.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/6032.html" rel="external">"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children", section on 'Microbiology'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gram-negative organisms on Gram stain</strong> – A second- or third-generation cephalosporin should be added to empiric antistaphylococcal therapy if gram-negative organisms are identified on Gram stain. Empiric antistaphylococcal therapy should be continued because Gram stain results are subject to observer misinterpretation.<em> </em></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Penetrating trauma or history of penetrating trauma</strong> – Penetrating trauma may cause polymicrobial infection. Empiric therapy should include coverage for <em>P. aeruginosa </em>as well as <em>S. aureus</em>. Options for empiric therapy include <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a> alone (for coverage against <em>P. aeruginosa</em> and MSSA) or combination therapy with cefepime or <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a> plus an agent with activity against MRSA (eg, <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a>, <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>). Pathogen-directed therapy should include agents directed against all organisms recovered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preschool children in day care</strong> – <em>K. kingae</em> should be considered as a possible pathogen in children 6 to 36 months of age (especially those attending day care and those with a history of oral ulcers preceding the onset of musculoskeletal findings) [<a href="#rid56">56-61</a>]. <em>K. kingae</em> usually is susceptible to cephalosporins (eg, <a class="drug drug_pediatric" data-topicid="13124" href="/d/drug information/13124.html" rel="external">cefazolin</a>, <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a>, <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a>) but consistently resistant to <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> and often resistant to <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> and antistaphylococcal penicillins (eg, <a class="drug drug_pediatric" data-topicid="12663" href="/d/drug information/12663.html" rel="external">oxacillin</a>, <a class="drug drug_pediatric" data-topicid="12626" href="/d/drug information/12626.html" rel="external">nafcillin</a>) [<a href="#rid57">57,58</a>].</p><p></p><p class="bulletIndent1">We generally do not provide initial empiric coverage for <em>K. kingae</em> in young children because most cases of bacterial arthritis in the United States are caused by <em>S. aureus</em> and other gram-positive pathogens. In addition, initial multidrug therapy may complicate transition to oral therapy if an organism is not identified in culture. <em>K. kingae</em> generally causes relatively mild musculoskeletal infections [<a href="#rid58">58</a>]. (See <a class="local">'Choice of oral regimen'</a> below.)</p><p></p><p class="bulletIndent1">For children between 6 and 36 months of age who require <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> or <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> for empiric coverage of CA-MRSA, empiric coverage for <em>K. kingae</em> with <a class="drug drug_pediatric" data-topicid="13124" href="/d/drug information/13124.html" rel="external">cefazolin</a> may be added if the child does not improve as expected. Alternatively, cefazolin may be substituted for vancomycin or clindamycin if CA-MRSA is not identified in cultures of blood, bone, or soft tissue aspirates. (See <a class="local">'Response to therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incomplete Hib immunization</strong> – Coverage for Hib (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a>, <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a>) should be added to the empiric regimen for children &lt;2 years of age who are incompletely immunized against Hib  (<a class="graphic graphic_table graphicRef95852" href="/d/graphic/95852.html" rel="external">table 6</a>) in areas where Hib immunization rates are low but is not necessary for those in areas with high Hib immunization rates. In the United States, local immunization coverage rates may be available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fimz-managers%2Fcoverage%2Fchildvaxview%2Finteractive-reports%2Findex.html&amp;token=6m20uI%2FmtLEXbah5KbJhwOzuFQVsug1S5MwBv2Ayh2Ec5snLhVG%2BS0aQpyN1zlgJWjRg6VCS%2BsIvzuAxHWB5%2Bq%2FAAOBHuWOt5%2BhzigksfXjrfLrkOftqn1iQI9hCVugz&amp;TOPIC_ID=6033" target="_blank">Centers for Disease Control and Prevention</a> or the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpatient-care%2Fimmunizations%2F&amp;token=IQxLzDq4doJGUgaZgeIY01qsm8D6OPt1e2CZs7qNDD9Vki1c5XPFvhIarxbXlaH%2FgCiVnpr391CqcLRvxCctPg%3D%3D&amp;TOPIC_ID=6033" target="_blank">American Academy of Pediatrics</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children at risk for penicillin-nonsusceptible pneumococcal arthritis</strong> – Empiric coverage for penicillin-nonsusceptible <em>S. pneumoniae</em> (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a>, <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a>) may be warranted in children [<a href="#rid62">62</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Younger than two years with incomplete pneumococcal immunization  (<a class="graphic graphic_table graphicRef95852" href="/d/graphic/95852.html" rel="external">table 6</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age two years or older with medical conditions that increase the risk of invasive pneumococcal disease  (<a class="graphic graphic_table graphicRef68655" href="/d/graphic/68655.html" rel="external">table 7</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Who received antibiotics within four weeks of diagnosis of bacterial arthritis</p><p></p><p class="bulletIndent1">In the era of routine pneumococcal vaccination, most cases of pneumococcal arthritis occur in children without risk factors and are caused by serotypes not included in the pneumococcal conjugate vaccine (especially 35B and 33F which were not included in the 10-valent or 13-valent vaccine)  (<a class="graphic graphic_table graphicRef77274" href="/d/graphic/77274.html" rel="external">table 8</a>) [<a href="#rid63">63</a>], In the United States, the 15-valent and 20-valent pneumococcal conjugate vaccines, which contain serotype 33F, were licensed in 2022 and 2023, respectively. (See  <a class="medical medical_review" href="/d/html/6053.html" rel="external">"Pneumococcal vaccination in children", section on 'Conjugate vaccines'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sickle cell disease</strong> – Coverage for <em>Salmonella</em> (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a>, <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a>) should be added to the empiric regimen for children with sickle cell disease or related hemoglobinopathies. (See  <a class="medical medical_review" href="/d/html/5937.html" rel="external">"Evaluation and management of fever in children and adults with sickle cell disease", section on 'Empiric antibiotic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recent gastrointestinal surgery or complex urinary tract anatomy</strong> – Patients with recent gastrointestinal surgery or complex urinary tract anatomy are at risk for infection with enteric gram-negative organisms or <em>Enterococcus</em>. Addition of <a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">ampicillin</a> and either 1) a third- or fourth-generation cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a>, <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a>, <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a>) or 2) an aminoglycoside (eg, <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a>) to the initial empiric regimen may be warranted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sexually active adolescents</strong> – Coverage for <em>N. gonorrhoeae </em>(eg, <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a>) should be added to antistaphylococcal coverage in sexually active adolescents [<a href="#rid64">64</a>]. Presumptive treatment for chlamydia should also be given unless it has been excluded microbiologically. (See  <a class="medical medical_review" href="/d/html/7603.html" rel="external">"Disseminated gonococcal infection", section on 'Initial antimicrobial therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Injection drug users</strong> – Organisms that cause infection among injecting drug users (IDU) vary markedly between different communities. <em>P. aeruginosa</em> has been frequently reported among IDUs with bacterial arthritis. If <em>P. aeruginosa</em> arthritis is a consideration, our initial empiric regime includes <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a> as well as antistaphylococcal coverage with <a class="drug drug_pediatric" data-topicid="12626" href="/d/drug information/12626.html" rel="external">nafcillin</a>/<a class="drug drug_pediatric" data-topicid="12663" href="/d/drug information/12663.html" rel="external">oxacillin</a> or <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>. (See  <a class="medical medical_review" href="/d/html/7643.html" rel="external">"Pseudomonas aeruginosa skin and soft tissue infections"</a> and  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"</a>.)</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Pathogen-directed therapy</span><span class="headingEndMark"> — </span>Pathogen-directed therapy is based upon culture and susceptibility results  (<a class="graphic graphic_table graphicRef71347" href="/d/graphic/71347.html" rel="external">table 9</a>). Consultation with an expert in infectious diseases is suggested for children with an inadequate response to therapy, unusual organisms (eg, <em>P. multocida</em>, <em>C. acnes</em>, fungal pathogens), immunocompromised individuals [<a href="#rid65">65</a>], and/or drug allergies. (See <a class="local">'Indications for consultation'</a> above.)</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Negative cultures</span><span class="headingEndMark"> — </span>No organism is identified in 30 to 50 percent of children with clinical bacterial arthritis [<a href="#rid41">41,66-68</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Improvement with empiric therapy</strong> – In patients who demonstrate clinical and laboratory improvement with empiric therapy, the initial empiric therapy is continued. Patients who are immunocompetent and fully immunized against Hib and <em>S. pneumoniae </em> (<a class="graphic graphic_table graphicRef95852" href="/d/graphic/95852.html" rel="external">table 6</a>) may be switched to oral therapy if the oral regimen provides the same spectrum of coverage as the initial parenteral empiric regimen. (See <a class="local">'Oral therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No improvement with empiric therapy</strong> – In patients who do not demonstrate clinical and laboratory improvement with empiric therapy, additional infectious agents and diagnoses other than bacterial arthritis must be considered. (See <a class="local">'Treatment failure'</a> below.)</p><p></p><p class="headingAnchor" id="H2304422496"><span class="h2">Oral therapy</span><span class="headingEndMark"> — </span>In infants and children ≥1 month, parenteral therapy is continued at least until clinical and laboratory improvement have been demonstrated, after which the balance of antibiotic therapy can be administered orally [<a href="#rid69">69</a>]. As long as the patient has demonstrated improvement, successful treatment does not require a minimum duration of parenteral therapy. In randomized and observational studies, treatment of bacterial arthritis in children with intravenous antibiotics for short periods (approximately seven days) followed by oral therapy was as successful as longer courses of parenteral therapy [<a href="#rid70">70-72</a>]. (See <a class="local">'Response to therapy'</a> below.)</p><p class="headingAnchor" id="H2819448550"><span class="h3">Prerequisites</span><span class="headingEndMark"> — </span>Our prerequisites for switching from parenteral to oral therapy include [<a href="#rid4">4,71-76</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The child is ≥1 month of age; (for infants younger than one month of age), we provide the entire course of antimicrobial therapy parenterally; the gastrointestinal absorption of oral antibiotics in neonates is unpredictable [<a href="#rid77">77,78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The child has improved as expected with parenteral therapy (eg, decreased swelling, tenderness, and erythema; improved joint mobility; decreased or absent fever; decreased CRP). (See <a class="local">'Response to therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The child is immunocompetent and fully immunized against Hib and <em>S. pneumoniae</em> for their age  (<a class="graphic graphic_table graphicRef95852" href="/d/graphic/95852.html" rel="external">table 6</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The child has demonstrated the ability to swallow and retain an appropriate oral medication; the initial doses of oral therapy should be administered while the child is in the hospital to ensure that the drug is tolerated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient and caregiver(s) have received appropriate education, are committed to the follow-up schedule, and are expected to adhere to the antimicrobial regimen. (See <a class="local">'Outpatient follow-up'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pathogen has been identified and an oral agent with appropriate coverage is available, or, if cultures are negative, the child has responded as expected to empiric parenteral therapy and an oral regimen with a spectrum similar to the parenteral regimen is available. (See <a class="local">'Response to therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical course has been uncomplicated.</p><p></p><p class="headingAnchor" id="H2881890919"><span class="h3">Choice of oral regimen</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agent(s)</strong> – The choice of agent(s) for oral therapy depends upon whether an organism was isolated from the synovial fluid, blood, or other culture. Additional considerations include the bioavailability and palatability of the oral medication. Consultation with an expert in infectious diseases may be helpful in choosing the optimal oral agent, particularly if the child has an unusual pathogen (eg, <em>P. multocida</em>, <em>C. acnes, </em>fungal organisms) or allergy to antibiotics. (See <a class="local">'Indications for consultation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Organism isolated</strong> – When an organism is isolated, the susceptibility pattern is used to determine an appropriate drug  (<a class="graphic graphic_table graphicRef71347" href="/d/graphic/71347.html" rel="external">table 9</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Organism not isolated</strong> – When an organism is not isolated, oral therapy is directed toward the most likely pathogen(s) given the child's age  (<a class="graphic graphic_table graphicRef53150" href="/d/graphic/53150.html" rel="external">table 1</a>) and clinical presentation  (<a class="graphic graphic_table graphicRef75192" href="/d/graphic/75192.html" rel="external">table 2</a>). The chosen regimen should have a spectrum similar to that provided by the parenteral therapy that was associated with improvement. As examples, a child who improved on <a class="drug drug_pediatric" data-topicid="13124" href="/d/drug information/13124.html" rel="external">cefazolin</a> may be switched to <a class="drug drug_pediatric" data-topicid="13138" href="/d/drug information/13138.html" rel="external">cephalexin</a>; a child who improved on parenteral <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> could be switched to oral clindamycin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – Given the possibility of concomitant osteomyelitis and the relatively low penetration of penicillins and certain cephalosporins into bone, antibiotics administered orally for bacterial arthritis are generally given in higher doses than those used for treatment of other infections and recommended in package inserts  (<a class="graphic graphic_table graphicRef58533" href="/d/graphic/58533.html" rel="external">table 10</a>) [<a href="#rid79">79-82</a>]. Doses of penicillins, <a class="drug drug_pediatric" data-topicid="13138" href="/d/drug information/13138.html" rel="external">cephalexin</a>, and <a class="drug drug_pediatric" data-topicid="13123" href="/d/drug information/13123.html" rel="external">cefadroxil</a> can be increased to 100 to 150 mg/kg per day without serious adverse side effects [<a href="#rid55">55,79</a>]. Monitoring drug levels may be helpful in exceptional cases if there is a concern about adequate absorption or adherence to the treatment regimen. Nonetheless, it is not generally necessary; clinical examination and laboratory monitoring for markers of inflammation provide sufficient evidence of the efficacy of treatment. (See <a class="local">'Drug monitoring'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration of first dose</strong> – We advise that the initial dose of oral therapy be administered while the child is in the hospital to ensure that the drug is tolerated. The child may be discharged home when they are able to tolerate the oral antibiotic and it is clear that the caregiver can administer oral therapy as prescribed. (See <a class="local">'Outpatient follow-up'</a> below.)</p><p></p><p class="headingAnchor" id="H2636361646"><span class="h3">Drug monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adequacy of therapy </strong>– We do not usually monitor drug levels for adequacy of therapy in children with bacterial arthritis. The use of oral antimicrobial agents to complete treatment for septic arthritis has been commonplace for decades and is nearly always associated with success [<a href="#rid29">29</a>]. Measurement of antibiotic levels may be helpful in select patients if there is a concern regarding adequate absorption or adherence to the treatment regimen. Assays are available for most of the antibiotics that are used routinely to treat bacterial arthritis (eg, <a class="drug drug_pediatric" data-topicid="13138" href="/d/drug information/13138.html" rel="external">cephalexin</a> and <a class="drug drug_pediatric" data-topicid="13227" href="/d/drug information/13227.html" rel="external">dicloxacillin</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Children who are being treated with oral antibiotic therapy for bacterial arthritis require monitoring for potential adverse effects. Adverse effects of high-dose antibiotic therapy include pancytopenia, leukopenia, hepatitis [<a href="#rid83">83</a>], hypersensitivity reactions, hepatotoxicity, kidney dysfunction, and antibiotic-associated diarrhea [<a href="#rid84">84,85</a>].</p><p></p><p class="bulletIndent1">We obtain complete blood count (CBC) with differential weekly initially, while the patient is receiving beta-lactam antibiotics (eg, penicillins, cephalosporins). It is also reasonable to obtain a biochemical profile, including serum aminotransferases, weekly while the patient is receiving beta-lactam antibiotics, although some experts only obtain serum aminotransferases in children with underlying liver disease. Some experts also obtain CBC with differential every one to two weeks for <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a>, although hematologic adverse effects are less of a concern. For <a class="drug drug_pediatric" data-topicid="12555" href="/d/drug information/12555.html" rel="external">linezolid</a>, CBCs should be monitored weekly for therapy beyond two weeks. (See <a class="local">'Outpatient follow-up'</a> below.)</p><p></p><p class="headingAnchor" id="H2588569268"><span class="h2">Outpatient parenteral therapy</span><span class="headingEndMark"> — </span>Outpatient parenteral antimicrobial therapy (OPAT) may be warranted for children ≥1 month of age who have improved as expected with parenteral therapy but do not meet the prerequisites for oral therapy. (See <a class="local">'Prerequisites'</a> above.)</p><p>Insertion of a percutaneously inserted central catheter facilitates prolonged administration of parenteral antibiotics and can be used for OPAT [<a href="#rid4">4</a>]. However, catheter-related complications (eg, malfunction, displacement, bloodstream infection) occur in 30 to 40 percent of children with osteoarticular infections who are treated with OPAT [<a href="#rid86">86,87</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Total duration</span><span class="headingEndMark"> — </span>The total duration of antimicrobial therapy for bacterial arthritis depends upon the pathogen and response to therapy. We provide the following general guidelines:</p><p class="bulletIndent1"><span class="glyph">●</span><em>S. aureus</em> – Minimum of three weeks</p><p class="bulletIndent1"><span class="glyph">●</span><em>S. pneumoniae</em>, GBS, group A <em>Streptococcus </em>– Two to three weeks</p><p class="bulletIndent1"><span class="glyph">●</span><em>K. kingae,</em> <em>N. meningitidis</em>, <em>H. influenzae</em> – Two to three weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Other gram-negative pathogens (eg, <em>Salmonella</em>) – Three weeks, particularly in the setting of penetrating trauma or gastrointestinal surgery</p><p class="bulletIndent1"><span class="glyph">●</span>Culture-negative arthritis – Two weeks</p><p></p><p>Longer courses may be necessary for bacterial arthritis of the hip [<a href="#rid20">20</a>] and for arthritis caused by <em>Enterobacteriaceae</em> or other unusual organisms [<a href="#rid8">8,73,88</a>]. (See <a class="local">'Indications for consultation'</a> above.)</p><p>Antimicrobial therapy may be discontinued if the ESR (if measured) and CRP have returned to normal by these time points and there is no radiographic evidence of osteomyelitis, which occurs concomitantly in as many as 64 percent of cases [<a href="#rid51">51,55,73,89-92</a>].</p><p>Culture-negative septic arthritis should be managed in a similar fashion; if no evidence of bony involvement is found and ESR and CRP have normalized by two to three weeks, the empiric treatment can be stopped.</p><p>Radiographs should be obtained two to three weeks into the course of treatment to look for bone changes indicative of osteomyelitis [<a href="#rid93">93</a>]. This is of particular concern in cases of septic arthritis of the shoulder and hip in which concomitant osteomyelitis is common [<a href="#rid24">24</a>]. Radiographic findings suggestive of osteomyelitis include lytic lesions  (<a class="graphic graphic_diagnosticimage graphicRef51834" href="/d/graphic/51834.html" rel="external">image 1</a>) and periosteal elevation  (<a class="graphic graphic_diagnosticimage graphicRef71349" href="/d/graphic/71349.html" rel="external">image 2</a>), thickening, or new bone formation [<a href="#rid94">94</a>]. Osteomyelitis may require surgical intervention or prolongation of antibiotic therapy. (See  <a class="medical medical_review" href="/d/html/6067.html" rel="external">"Hematogenous osteomyelitis in children: Evaluation and diagnosis", section on 'Advanced imaging'</a> and  <a class="medical medical_review" href="/d/html/5958.html" rel="external">"Hematogenous osteomyelitis in children: Management"</a>.)</p><p>Bacterial arthritis with concomitant osteomyelitis is associated with a worse prognosis than bacterial arthritis alone [<a href="#rid93">93</a>]. (See <a class="local">'Prognostic factors'</a> below.)</p><p>The suggested treatment durations are based on studies performed in the 1970s. A multicenter randomized open-label trial performed in Finland between 1983 and 2005 suggested that 10 days of antimicrobial therapy may be adequate for patients with culture-positive bacterial arthritis without adjacent osteomyelitis who demonstrate clinical improvement and either CRP &lt;2 mg/dL (20 mg/L) or two normal CRP levels [<a href="#rid20">20</a>]. However, no cases of MRSA infections were encountered in this series, and 15 percent of children with hip involvement required extension of therapy beyond the planned duration [<a href="#rid95">95</a>]. Given these limitations and the paucity of data from infants (in whom septic arthritis of the hip is frequently associated with sequelae), we continue to treat bacterial arthritis for two to three weeks for most pathogens, and three weeks as a minimum for <em>S. aureus</em>.</p><p class="headingAnchor" id="H26"><span class="h1">ADJUNCTIVE THERAPIES</span></p><p class="headingAnchor" id="H27"><span class="h2">Analgesia</span><span class="headingEndMark"> — </span>Pain management is an important aspect of therapy for bacterial arthritis. Opioid therapy may be necessary during initial hospitalization; consultation with the pain management service may be helpful. After discharge, <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> or <a class="drug drug_pediatric" data-topicid="13371" href="/d/drug information/13371.html" rel="external">ibuprofen</a> may be used for pain control [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H28"><span class="h2">Physical therapy</span><span class="headingEndMark"> — </span>Attention must be paid to joint position and rapid mobilization to prevent contractures and promote optimal nutrition to the articular cartilage. Physical therapy may be helpful in children who are reluctant to use the joint.</p><p>Once discharged home, the child initially may require a wheelchair or walker and continued physical therapy.</p><p class="headingAnchor" id="H29"><span class="h2">Anti-inflammatory agents</span><span class="headingEndMark"> — </span>The inflammatory response is an important component of the pathogenesis of bacterial arthritis and accounts for at least a portion of the long-term morbidity. Some experts recommend routine nonsteroidal anti-inflammatory drugs (NSAIDs), but there are no data to demonstrate that NSAIDS improve recovery or alter outcomes. The author of this topic recommends nonselective NSAIDs if necessary for pain management.</p><p>We do not routinely suggest adjunctive glucocorticoid therapy for children with septic arthritis. Although randomized trials and observational studies comparing <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> with placebo in children with septic arthritis have suggested potential benefits, long-term outcomes were inconsistent [<a href="#rid96">96-99</a>]. A meta-analysis that included two randomized trials (a total of 149 patients) found both trials to be at high risk of attrition bias and selective outcome reporting [<a href="#rid99">99</a>]. Additional limitations include the absence of cases of methicillin-resistant <em>S. aureus</em> and the relatively prolonged duration of parenteral antibiotics in some patients. Moreover, the effects of dexamethasone were not compared with those of nonsteroidal anti-inflammatory agents, which are recommended as adjunctive therapy by some experts.</p><p class="headingAnchor" id="H30"><span class="h1">RESPONSE TO THERAPY</span></p><p class="headingAnchor" id="H31"><span class="h2">Monitoring response</span><span class="headingEndMark"> — </span>The response to therapy is assessed with serial clinical and laboratory evaluations. During hospitalization, we monitor clinical status (eg, fever; joint pain, swelling, erythema, and mobility) at least daily. We monitor peripheral white blood cell (WBC) count and/or C-reactive protein (CRP) every two to three days and/or if clinical status worsens. We monitor synovial fluid WBC count and culture (if repeated aspirations are necessary).</p><p>Monitoring during outpatient oral or parenteral therapy is discussed below. (See <a class="local">'Outpatient follow-up'</a> below.)</p><p class="headingAnchor" id="H1608783165"><span class="h2">Expected response</span><span class="headingEndMark"> — </span>Clinical and laboratory improvement is indicated by:</p><p class="bulletIndent1"><span class="glyph">●</span>Resolution of fever – Fever usually resolves within three to five days of initiation of treatment [<a href="#rid4">4,70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improved joint symptoms – Improvement in joint symptoms (pain, swelling, erythema, mobility) usually occurs within two days of initiation of treatment. The time required for resolution of symptoms and sterilization of the joint fluid is proportional to the duration of symptoms before initiation of appropriate therapy and the synovial fluid WBC count at the time of diagnosis [<a href="#rid100">100-102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normalization of the peripheral WBC count and decreased ESR and/or CRP – CRP is more useful than ESR for monitoring acute response to treatment. WBC counts, if initially abnormal, normalize within one week of initiation of treatment [<a href="#rid103">103</a>]. Even with appropriate treatment, the ESR may continue to rise for three to five days, whereas CRP peaks within 36 to 50 hours of onset of infection and quickly falls to normal with appropriate therapy [<a href="#rid9">9,103</a>]. ESR remains useful for determining the duration of therapy since it normalizes as inflammation resolves. Although many children still have a mildly elevated ESR at the end of the prescribed treatment course, they may not require additional therapy if no evidence of associated osteomyelitis is revealed by radiographs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decrease in synovial fluid WBC count and sterilization of synovial fluid – In joints that initially were drained with needle aspiration, synovial fluid may reaccumulate, requiring repeated drainage. Infected knees, in particular, may continue to accumulate fluid for 7 to 10 days. When available (from repeat aspiration or a surgical drain), serial synovial fluid analyses should demonstrate sterilization and a decreasing WBC count within one to two days.</p><p></p><p class="headingAnchor" id="H32"><span class="h2">Treatment failure</span><span class="headingEndMark"> — </span>Treatment failure may be indicated by:</p><p class="bulletIndent1"><span class="glyph">●</span>Lack of clinical improvement</p><p class="bulletIndent1"><span class="glyph">●</span>CRP that continues to rise three to five days after initiation of therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Persistently elevated ESR, CRP, peripheral WBC count, or synovial fluid WBC count</p><p class="bulletIndent1"><span class="glyph">●</span>Failure to sterilize the synovial fluid in the expected period of one to two days (if repeat cultures are obtained)</p><p></p><p>Patients who do not respond to empiric or pathogen-directed therapy as expected should be reevaluated. They may require arthrotomy and/or adjustment of antimicrobial therapy.</p><p>Reevaluation should generally include magnetic resonance imaging for evidence of osteomyelitis with abscess; review of the history for exposure to unusual organisms (eg, <em>P</em>.<em> multocida</em>, <em>C. acnes</em>) or penetrating trauma; and reconsideration of other conditions in the differential diagnosis. (See  <a class="medical medical_review" href="/d/html/6032.html" rel="external">"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children", section on 'Microbiology'</a> and  <a class="medical medical_review" href="/d/html/6030.html" rel="external">"Bacterial arthritis: Clinical features and diagnosis in infants and children", section on 'Differential diagnosis'</a>.)</p><p>For patients who do not improve after 48 hours of antibiotic therapy or have persistent positive cultures despite appropriate antimicrobial therapy and multiple needle aspirations, arthrotomy may be necessary to ensure thorough debridement of infected tissue, breakdown of loculations, and irrigation of the joint space.</p><p>For patients with failure to improve despite appropriate pathogen-directed therapy, it may be helpful to monitor drug levels to ensure adequate serum levels. (See <a class="local">'Drug monitoring'</a> above.)</p><p>For patients with negative cultures, more aggressive attempts to isolate or identify unusual pathogens and fastidious organisms (eg, <em>K. kingae</em>) may be warranted  (<a class="graphic graphic_table graphicRef75192" href="/d/graphic/75192.html" rel="external">table 2</a>). This may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Aspiration of any involved soft tissue or bone biopsy for histopathologic staining and bacterial culture.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Molecular testing is especially helpful for identifying <em>K. kingae</em> in synovial fluid that is culture negative. (See  <a class="medical medical_review" href="/d/html/6030.html" rel="external">"Bacterial arthritis: Clinical features and diagnosis in infants and children", section on 'Synovial fluid'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Appropriate serologic testing for children with potential exposure to <em>Coccidioides</em> or <em>Brucella</em>. (See  <a class="medical medical_review" href="/d/html/2420.html" rel="external">"Coccidioidomycosis: Laboratory diagnosis and screening"</a> and  <a class="medical medical_review" href="/d/html/2449.html" rel="external">"Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis"</a> and  <a class="medical medical_review" href="/d/html/3140.html" rel="external">"Brucellosis: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculosis testing if <em>Mycobacterium tuberculosis</em> is suspected. (See  <a class="medical medical_review" href="/d/html/8007.html" rel="external">"Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p>If the more aggressive evaluation does not identify an organism, broadening of empiric therapy to include organisms not covered by the initial regimen (eg, <em>K. kingae</em> in patients initially treated with <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>, <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a>, <a class="drug drug_pediatric" data-topicid="12626" href="/d/drug information/12626.html" rel="external">nafcillin</a>, or <a class="drug drug_pediatric" data-topicid="12663" href="/d/drug information/12663.html" rel="external">oxacillin</a>) may be indicated.</p><p class="headingAnchor" id="H33"><span class="h1">OUTPATIENT FOLLOW-UP</span><span class="headingEndMark"> — </span>We see children who are being treated for bacterial arthritis as outpatients approximately one week after discharge from the hospital and at one- to two-week intervals thereafter.</p><p>We monitor them for continued clinical improvement (including the need to initiate or continue physical therapy) and for complications related to high-dose antibiotic therapy, such as cytopenias, hepatitis [<a href="#rid83">83</a>], impaired liver or renal function, antibiotic-associated diarrhea, and pseudomembranous colitis.</p><p>We obtain complete blood count with differential, erythrocyte sedimentation rate, and C-reactive protein at each visit. It is also reasonable to obtain a biochemical profile, including serum aminotransferases, weekly while the patient is receiving beta-lactam antibiotics, although some experts only obtain serum aminotransferases in children with underlying liver disease. If patients are not improving as expected after being transitioned to oral therapy, it may be advisable to revert to intravenous therapy. (See <a class="local">'Treatment failure'</a> above.)</p><p>After treatment is discontinued, children generally should be monitored for long-term complications at routine well-child care visits. Those who are at high risk of damage to cartilage (eg, delayed recognition of septic arthritis of the hip for three or more days) should be monitored by an orthopedic surgeon with experience in pediatrics. (See <a class="local">'Complications'</a> below.)</p><p class="headingAnchor" id="H1733119032"><span class="h1">OUTCOME</span></p><p class="headingAnchor" id="H3138986219"><span class="h2">Complications</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Short-term complications </strong>– Short-term complications of bacterial osteoarticular infections include sepsis, septic shock, deep vein thrombosis, and septic pulmonary emboli [<a href="#rid104">104,105</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term complications </strong>– Potential long-term complications of bacterial arthritis include [<a href="#rid1">1,22,24,94,106-108</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avascular necrosis</p><p class="bulletIndent2"><span class="glyph">•</span>Joint laxity, subluxation, or dislocation</p><p class="bulletIndent2"><span class="glyph">•</span>Limited range of motion of the joint </p><p class="bulletIndent2"><span class="glyph">•</span>Limb-length discrepancy or angular deformities (if the growth plate is involved)</p><p class="bulletIndent2"><span class="glyph">•</span>Enlargement of the femoral head (coxa magna) in bacterial arthritis of the hip</p><p class="bulletIndent2"><span class="glyph">•</span>Pathologic fractures</p><p class="bulletIndent2"><span class="glyph">•</span>Premature osteoarthritis</p><p></p><p>The estimated rate of complications ranges from 10 to 29 percent, depending upon the patient population, the involved joint, and the duration of follow-up (prolonged follow-up may be necessary to detect some complications) [<a href="#rid1">1,15,32,67,92,94,109-111</a>]. Studies published after 2015 have reported lower rates of complication (4 to 5 percent), possibly reflecting more awareness and/or improved management strategies [<a href="#rid32">32,92</a>]. </p><p>Even with appropriate management, up to 40 percent of patients with hip involvement and 10 percent of patients with knee involvement develop significant complications [<a href="#rid11">11,112-114</a>].</p><p class="headingAnchor" id="H39"><span class="h2">Prognostic factors</span><span class="headingEndMark"> — </span>In observational studies, the following factors were associated with long-term complications [<a href="#rid66">66,67,88,111,114-119</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Duration of symptoms before treatment, particularly if &gt;4 to 7 days (ie, a delay in diagnosis)</p><p class="bulletIndent1"><span class="glyph">●</span>Involvement of the hip</p><p class="bulletIndent1"><span class="glyph">●</span>Involvement of the hip or shoulder with concomitant osteomyelitis</p><p class="bulletIndent1"><span class="glyph">●</span>Age less than one year, particularly less than one month</p><p class="bulletIndent1"><span class="glyph">●</span>Isolation of <em>S. aureus</em> or Enterobacteriaceae compared with other pathogens</p><p></p><p>Factors that do not appear to be related to outcome include:</p><p class="bulletIndent1"><span class="glyph">●</span>The mode of drainage, provided that adequate drainage is achieved</p><p class="bulletIndent1"><span class="glyph">●</span>The choice of antibiotic, provided that it is effective against the infecting organism</p><p></p><p class="headingAnchor" id="H1024602637"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/126523.html" rel="external">"Society guideline links: Septic arthritis and osteomyelitis in children"</a>.)</p><p class="headingAnchor" id="H82871981"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83255.html" rel="external">"Patient education: Septic arthritis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H40"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Bacterial arthritis requires prompt recognition and management. Drainage of joint fluid and antimicrobial therapy are the cornerstones of therapy. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drainage</strong> – Decisions regarding the optimal drainage procedure should be individualized. We prefer arthrotomy for children with bacterial arthritis of the hip or shoulder, penetrating trauma, concomitant osteomyelitis, and/or large amount of debris or loculations. For other joints, arthroscopy and needle aspiration are alternatives to arthrotomy. (See <a class="local">'Drainage'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic therapy</strong> – Antibiotic therapy is necessary to sterilize the joint fluid. Antibiotics should be administered as soon as possible after blood and synovial fluid cultures have been obtained. (See <a class="local">'Antibiotic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Empiric parenteral therapy – We include coverage for <em>Staphylococcus aureus </em>in the empiric regimen for children of all ages  (<a class="graphic graphic_algorithm graphicRef120251" href="/d/graphic/120251.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef112013" href="/d/graphic/112013.html" rel="external">table 3</a>). Coverage for additional pathogens may be necessary based upon the child's age  (<a class="graphic graphic_table graphicRef53150" href="/d/graphic/53150.html" rel="external">table 1</a>), particular clinical circumstances  (<a class="graphic graphic_table graphicRef75192" href="/d/graphic/75192.html" rel="external">table 2</a>), and Gram stain  (<a class="graphic graphic_table graphicRef112013" href="/d/graphic/112013.html" rel="external">table 3</a>). Initial antimicrobial therapy for bacterial arthritis usually is administered parenterally  (<a class="graphic graphic_table graphicRef51833" href="/d/graphic/51833.html" rel="external">table 4</a>). (See <a class="local">'Empiric parenteral therapy'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pathogen-directed therapy – The antimicrobial regimen can be tailored to a specific pathogen when culture and susceptibility results are available  (<a class="graphic graphic_table graphicRef71347" href="/d/graphic/71347.html" rel="external">table 9</a>). Children whose cultures remain negative and improve with empiric therapy usually are continued on the empiric parenteral regimen. (See <a class="local">'Pathogen-directed therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Route and total duration of therapy – In infants &lt;1 month of age, we provide the entire course of antimicrobial therapy parenterally. Infants who are age one month or older and children may be switched to oral therapy  (<a class="graphic graphic_table graphicRef58533" href="/d/graphic/58533.html" rel="external">table 10</a>) if they have demonstrated clinical and laboratory improvement and meet prerequisites for oral therapy. (See <a class="local">'Oral therapy'</a> above and <a class="local">'Outpatient parenteral therapy'</a> above and <a class="local">'Total duration'</a> above.)</p><p></p><p class="bulletIndent2"><em>S. aureus</em> arthritis is usually treated for at least three weeks; other causes of bacterial arthritis and culture-negative arthritis are usually treated for two to three weeks. Antimicrobial therapy may be discontinued if the erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP) have returned to normal by these time points and there is no radiographic evidence of unsuspected osteomyelitis. (See <a class="local">'Total duration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to therapy</strong> – Children receiving appropriate antimicrobial therapy generally demonstrate clinical improvement within three to five days. Clinical improvement is demonstrated by decreased fever; improved joint pain, swelling, erythema, and range of motion; and decreased peripheral white blood cell (WBC) count, ESR and/or CRP, and synovial fluid WBC count and culture (if obtained). (See <a class="local">'Response to therapy'</a> above.)</p><p></p><p class="bulletIndent1">Patients who do not respond to treatment as expected should be reevaluated. They may require arthrotomy and/or adjustment of antimicrobial therapy. (See <a class="local">'Treatment failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outpatient follow-up</strong> – We see children who are being treated for bacterial arthritis as outpatients approximately one week after discharge from the hospital and at one- to two-week intervals thereafter. We monitor them for clinical improvement and complications of high-dose antibiotic therapy. We obtain a complete blood count with differential, ESR, and CRP at each visit. It is also reasonable to obtain a biochemical profile, including serum aminotransferases, weekly while the patient is receiving beta-lactam antibiotics, although some experts only obtain serum aminotransferases in children with underlying liver disease. (See <a class="local">'Outpatient follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – Residual joint dysfunction is a major morbidity for children with septic arthritis. Factors related to poor outcome include duration of symptoms before treatment, involvement of the hip, involvement of the hip or shoulder with concomitant osteomyelitis, and age younger than one year. (See <a class="local">'Outcome'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nade S. Septic arthritis. Best Pract Res Clin Rheumatol 2003; 17:183.</a></li><li class="breakAll">Krogstad P. Septic arthritis. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 8th ed, Cherry JD, Harrison G, Kaplan SL, et al (Eds), Elsevier, Philadelphia 2018. p.529.</li><li class="breakAll">Hong DK, Gutierrez K. Infectious and inflammatory arthritis. In: Principles and Practice of Pediatric Infectious Diseases, 5th ed, Long SS, Prober CG, Fischer M (Eds), Elsevier, Philadelphia 2018. p.487.</li><li><a class="nounderline abstract_t">Kocher MS, Mandiga R, Murphy JM, et al. A clinical practice guideline for treatment of septic arthritis in children: efficacy in improving process of care and effect on outcome of septic arthritis of the hip. J Bone Joint Surg Am 2003; 85-A:994.</a></li><li><a class="nounderline abstract_t">Smith RL, Schurman DJ. Bacterial arthritis. A staphylococcal proteoglycan-releasing factor. Arthritis Rheum 1986; 29:1378.</a></li><li><a class="nounderline abstract_t">Riegels-Nielsen P, Frimodt-Møller N, Sørensen M, Jensen JS. Antibiotic treatment insufficient for established septic arthritis. Staphylococcus aureus experiments in rabbits. Acta Orthop Scand 1989; 60:113.</a></li><li><a class="nounderline abstract_t">Nord KD, Dore DD, Deeney VF, et al. Evaluation of treatment modalities for septic arthritis with histological grading and analysis of levels of uronic acid, neutral protease, and interleukin-1. J Bone Joint Surg Am 1995; 77:258.</a></li><li><a class="nounderline abstract_t">Saavedra-Lozano J, Falup-Pecurariu O, Faust SN, et al. Bone and Joint Infections. Pediatr Infect Dis J 2017; 36:788.</a></li><li class="breakAll">Stans AA. Musculoskeletal infection. In: Lovell and Winter’s Pediatric Orthopaedics, 7th ed, Weinstein SL, Flynn JM (Eds), Wolters Kluwer Health, Philadelphia 2014. p.369.</li><li><a class="nounderline abstract_t">Mathews CJ, Coakley G. Septic arthritis: current diagnostic and therapeutic algorithm. Curr Opin Rheumatol 2008; 20:457.</a></li><li><a class="nounderline abstract_t">Morrey BF, Bianco AJ Jr, Rhodes KH. Septic arthritis in children. Orthop Clin North Am 1975; 6:923.</a></li><li><a class="nounderline abstract_t">Herndon WA, Knauer S, Sullivan JA, Gross RH. Management of septic arthritis in children. J Pediatr Orthop 1986; 6:576.</a></li><li><a class="nounderline abstract_t">Goldenberg DL, Brandt KD, Cohen AS, Cathcart ES. Treatment of septic arthritis: comparison of needle aspiration and surgery as initial modes of joint drainage. Arthritis Rheum 1975; 18:83.</a></li><li><a class="nounderline abstract_t">Daniel D, Akeson W, Amiel D, et al. Lavage of septic joints in rabbits: effects of chondrolysis. J Bone Joint Surg Am 1976; 58:393.</a></li><li><a class="nounderline abstract_t">Smith SP, Thyoka M, Lavy CB, Pitani A. Septic arthritis of the shoulder in children in Malawi. A randomised, prospective study of aspiration versus arthrotomy and washout. J Bone Joint Surg Br 2002; 84:1167.</a></li><li><a class="nounderline abstract_t">Stanitski CL, Harvell JC, Fu FH. Arthroscopy in acute septic knees. Management in pediatric patients. Clin Orthop Relat Res 1989; :209.</a></li><li><a class="nounderline abstract_t">Johns B, Loewenthal M, Ho E, Dewar D. Arthroscopic Versus Open Treatment for Acute Septic Arthritis of the Knee in Children. Pediatr Infect Dis J 2018; 37:413.</a></li><li><a class="nounderline abstract_t">El-Sayed AM. Treatment of early septic arthritis of the hip in children: comparison of results of open arthrotomy versus arthroscopic drainage. J Child Orthop 2008; 2:229.</a></li><li><a class="nounderline abstract_t">Thompson RM, Gourineni P. Arthroscopic Treatment of Septic Arthritis in Very Young Children. J Pediatr Orthop 2017; 37:e53.</a></li><li><a class="nounderline abstract_t">Peltola H, Pääkkönen M, Kallio P, et al. Prospective, randomized trial of 10 days versus 30 days of antimicrobial treatment, including a short-term course of parenteral therapy, for childhood septic arthritis. Clin Infect Dis 2009; 48:1201.</a></li><li><a class="nounderline abstract_t">Broy SB, Schmid FR. A comparison of medical drainage (needle aspiration) and surgical drainage (arthrotomy or arthroscopy) in the initial treatment of infected joints. Clin Rheum Dis 1986; 12:501.</a></li><li><a class="nounderline abstract_t">Wenger DR. Childhood hip sepsis: improving the yield of good results. Instr Course Lect 1985; 34:457.</a></li><li><a class="nounderline abstract_t">Fabry G, Meire E. Septic arthritis of the hip in children: poor results after late and inadequate treatment. J Pediatr Orthop 1983; 3:461.</a></li><li><a class="nounderline abstract_t">Belthur MV, Palazzi DL, Miller JA, et al. A clinical analysis of shoulder and hip joint infections in children. J Pediatr Orthop 2009; 29:828.</a></li><li><a class="nounderline abstract_t">Forward DP, Hunter JB. Arthroscopic washout of the shoulder for septic arthritis in infants. A new technique. J Bone Joint Surg Br 2002; 84:1173.</a></li><li><a class="nounderline abstract_t">Kim SJ, Choi NH, Ko SH, et al. Arthroscopic treatment of septic arthritis of the hip. Clin Orthop Relat Res 2003; :211.</a></li><li><a class="nounderline abstract_t">Nusem I, Jabur MK, Playford EG. Arthroscopic treatment of septic arthritis of the hip. Arthroscopy 2006; 22:902.e1.</a></li><li><a class="nounderline abstract_t">Chung WK, Slater GL, Bates EH. Treatment of septic arthritis of the hip by arthroscopic lavage. J Pediatr Orthop 1993; 13:444.</a></li><li><a class="nounderline abstract_t">Pääkkönen M, Kallio MJ, Peltola H, Kallio PE. Pediatric septic hip with or without arthrotomy: retrospective analysis of 62 consecutive nonneonatal culture-positive cases. J Pediatr Orthop B 2010; 19:264.</a></li><li><a class="nounderline abstract_t">Givon U, Liberman B, Schindler A, et al. Treatment of septic arthritis of the hip joint by repeated ultrasound-guided aspirations. J Pediatr Orthop 2004; 24:266.</a></li><li><a class="nounderline abstract_t">Griffet J, Oborocianu I, Rubio A, et al. Percutaneous aspiration irrigation drainage technique in the management of septic arthritis in children. J Trauma 2011; 70:377.</a></li><li><a class="nounderline abstract_t">Calvo C, Núñez E, Camacho M, et al. Epidemiology and Management of Acute, Uncomplicated Septic Arthritis and Osteomyelitis: Spanish Multicenter Study. Pediatr Infect Dis J 2016; 35:1288.</a></li><li><a class="nounderline abstract_t">Sanpera I, Raluy-Collado D, Sanpera-Iglesias J. Arthroscopy for hip septic arthritis in children. Orthop Traumatol Surg Res 2016; 102:87.</a></li><li><a class="nounderline abstract_t">Wilson NI, Di Paola M. Acute septic arthritis in infancy and childhood. 10 years' experience. J Bone Joint Surg Br 1986; 68:584.</a></li><li><a class="nounderline abstract_t">Pioro MH, Mandell BF. Septic arthritis. Rheum Dis Clin North Am 1997; 23:239.</a></li><li><a class="nounderline abstract_t">Goldenberg DL, Reed JI. Bacterial arthritis. N Engl J Med 1985; 312:764.</a></li><li><a class="nounderline abstract_t">Kang SN, Sanghera T, Mangwani J, et al. The management of septic arthritis in children: systematic review of the English language literature. J Bone Joint Surg Br 2009; 91:1127.</a></li><li><a class="nounderline abstract_t">Fink CW, Nelson JD. Septic arthritis and osteomyelitis in children. Clin Rheum Dis 1986; 12:423.</a></li><li><a class="nounderline abstract_t">Baciocco EA, Iles RL. Ampicillin and kanamycin concentrations in joint fluid. Clin Pharmacol Ther 1971; 12:858.</a></li><li><a class="nounderline abstract_t">Balboni V, Shapiro IM, Kydd DM. The penetration of penicillin into joint fluid following intramuscular administration. Am J Med Sci 1945; 210:588.</a></li><li><a class="nounderline abstract_t">Nelson JD. The bacterial etiology and antibiotic management of septic arthritis in infants and children. Pediatrics 1972; 50:437.</a></li><li><a class="nounderline abstract_t">Plott MA, Roth H. Penetration of clindamycin into synovial fluid. Clin Pharmacol Ther 1970; 11:577.</a></li><li><a class="nounderline abstract_t">Nelson JD. Antibiotic concentrations in septic joint effusions. N Engl J Med 1971; 284:349.</a></li><li><a class="nounderline abstract_t">Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics 2009; 123:e609.</a></li><li><a class="nounderline abstract_t">Waldvogel FA, Papageorgiou PS. Osteomyelitis: the past decade. N Engl J Med 1980; 303:360.</a></li><li><a class="nounderline abstract_t">Guilbert J, Meau-Petit V, de Labriolle-Vaylet C, et al. [Coagulase-negative staphylococcal osteomyelitis in preterm infants: a proposal for a diagnostic procedure]. Arch Pediatr 2010; 17:1473.</a></li><li><a class="nounderline abstract_t">Eggink BH, Rowen JL. Primary osteomyelitis and suppurative arthritis caused by coagulase-negative staphylococci in a preterm neonate. Pediatr Infect Dis J 2003; 22:572.</a></li><li><a class="nounderline abstract_t">Bowerman SG, Green NE, Mencio GA. Decline of bone and joint infections attributable to haemophilus influenzae type b. Clin Orthop Relat Res 1997; :128.</a></li><li><a class="nounderline abstract_t">Luhmann JD, Luhmann SJ. Etiology of septic arthritis in children: an update for the 1990s. Pediatr Emerg Care 1999; 15:40.</a></li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Carrillo-Marquez MA, Hulten KG, Hammerman W, et al. USA300 is the predominant genotype causing Staphylococcus aureus septic arthritis in children. Pediatr Infect Dis J 2009; 28:1076.</a></li><li><a class="nounderline abstract_t">Chen CJ, Chiu CH, Lin TY, et al. Experience with linezolid therapy in children with osteoarticular infections. Pediatr Infect Dis J 2007; 26:985.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Farrell DJ, Sader HS, Jones RN. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis 2012; 55 Suppl 3:S187.</a></li><li><a class="nounderline abstract_t">Williams AW, Newman PM, Ocheltree S, et al. Ceftaroline Fosamil Use in 2 Pediatric Patients With Invasive Methicillin-Resistant Staphylococcus aureus Infections. J Pediatr Pharmacol Ther 2015; 20:476.</a></li><li><a class="nounderline abstract_t">Peltola H, Pääkkönen M, Kallio P, et al. Clindamycin vs. first-generation cephalosporins for acute osteoarticular infections of childhood--a prospective quasi-randomized controlled trial. Clin Microbiol Infect 2012; 18:582.</a></li><li><a class="nounderline abstract_t">Kiang KM, Ogunmodede F, Juni BA, et al. Outbreak of osteomyelitis/septic arthritis caused by Kingella kingae among child care center attendees. Pediatrics 2005; 116:e206.</a></li><li><a class="nounderline abstract_t">Yagupsky P. Antibiotic susceptibility of Kingella kingae isolates from children with skeletal system infections. Pediatr Infect Dis J 2012; 31:212.</a></li><li><a class="nounderline abstract_t">Yagupsky P, Porsch E, St Geme JW 3rd. Kingella kingae: an emerging pathogen in young children. Pediatrics 2011; 127:557.</a></li><li><a class="nounderline abstract_t">Dubnov-Raz G, Ephros M, Garty BZ, et al. Invasive pediatric Kingella kingae Infections: a nationwide collaborative study. Pediatr Infect Dis J 2010; 29:639.</a></li><li><a class="nounderline abstract_t">Mallet C, Ceroni D, Litzelmann E, et al. Unusually severe cases of Kingella kingae osteoarticular infections in children. Pediatr Infect Dis J 2014; 33:1.</a></li><li><a class="nounderline abstract_t">Amit U, Flaishmakher S, Dagan R, et al. Age-Dependent Carriage of Kingella kingae in Young Children and Turnover of Colonizing Strains. J Pediatric Infect Dis Soc 2014; 3:160.</a></li><li><a class="nounderline abstract_t">Bradley JS, Kaplan SL, Tan TQ, et al. Pediatric pneumococcal bone and joint infections. The Pediatric Multicenter Pneumococcal Surveillance Study Group (PMPSSG). Pediatrics 1998; 102:1376.</a></li><li><a class="nounderline abstract_t">Olarte L, Romero J, Barson W, et al. Osteoarticular Infections Caused by Streptococcus pneumoniae in Children in the Post-Pneumococcal Conjugate Vaccine Era. Pediatr Infect Dis J 2017; 36:1201.</a></li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Wang DA, Tambyah PA. Septic arthritis in immunocompetent and immunosuppressed hosts. Best Pract Res Clin Rheumatol 2015; 29:275.</a></li><li><a class="nounderline abstract_t">Barton LL, Dunkle LM, Habib FH. Septic arthritis in childhood. A 13-year review. Am J Dis Child 1987; 141:898.</a></li><li><a class="nounderline abstract_t">Welkon CJ, Long SS, Fisher MC, Alburger PD. Pyogenic arthritis in infants and children: a review of 95 cases. Pediatr Infect Dis 1986; 5:669.</a></li><li><a class="nounderline abstract_t">Wiley JJ, Fraser GA. Septic arthritis in childhood. Can J Surg 1979; 22:326.</a></li><li><a class="nounderline abstract_t">Ballock RT, Newton PO, Evans SJ, et al. A comparison of early versus late conversion from intravenous to oral therapy in the treatment of septic arthritis. J Pediatr Orthop 2009; 29:636.</a></li><li><a class="nounderline abstract_t">Newton PO, Ballock RT, Bradley JS. Oral antibiotic therapy of bacterial arthritis. Pediatr Infect Dis J 1999; 18:1102.</a></li><li><a class="nounderline abstract_t">Jaberi FM, Shahcheraghi GH, Ahadzadeh M. Short-term intravenous antibiotic treatment of acute hematogenous bone and joint infection in children: a prospective randomized trial. J Pediatr Orthop 2002; 22:317.</a></li><li><a class="nounderline abstract_t">Kim HK, Alman B, Cole WG. A shortened course of parenteral antibiotic therapy in the management of acute septic arthritis of the hip. J Pediatr Orthop 2000; 20:44.</a></li><li><a class="nounderline abstract_t">Tetzlaff TR, McCracken GH Jr, Nelson JD. Oral antibiotic therapy for skeletal infections of children. II. Therapy of osteomyelitis and suppurative arthritis. J Pediatr 1978; 92:485.</a></li><li><a class="nounderline abstract_t">Kolyvas E, Ahronheim G, Marks MI, et al. Oral antibiotic therapy of skeletal infections in children. Pediatrics 1980; 65:867.</a></li><li><a class="nounderline abstract_t">Arnold JC, Cannavino CR, Ross MK, et al. Acute bacterial osteoarticular infections: eight-year analysis of C-reactive protein for oral step-down therapy. Pediatrics 2012; 130:e821.</a></li><li><a class="nounderline abstract_t">Chou AC, Mahadev A. The Use of C-reactive Protein as a Guide for Transitioning to Oral Antibiotics in Pediatric Osteoarticular Infections. J Pediatr Orthop 2016; 36:173.</a></li><li><a class="nounderline abstract_t">Perkins MD, Edwards KM, Heller RM, Green NE. Neonatal group B streptococcal osteomyelitis and suppurative arthritis. Outpatient therapy. Clin Pediatr (Phila) 1989; 28:229.</a></li><li><a class="nounderline abstract_t">Schwartz GJ, Hegyi T, Spitzer A. Subtherapeutic dicloxacillin levels in a neonate: possible mechanisms. J Pediatr 1976; 89:310.</a></li><li><a class="nounderline abstract_t">Nelson JD, Bucholz RW, Kusmiesz H, Shelton S. Benefits and risks of sequential parenteral--oral cephalosporin therapy for suppurative bone and joint infections. J Pediatr Orthop 1982; 2:255.</a></li><li><a class="nounderline abstract_t">Bryson YJ, Connor JD, LeClerc M, Giammona ST. High-dose oral dicloxacillin treatment of acute staphylococcal osteomyelitis in children. J Pediatr 1979; 94:673.</a></li><li><a class="nounderline abstract_t">Martínez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22:593.</a></li><li><a class="nounderline abstract_t">Landersdorfer CB, Bulitta JB, Kinzig M, et al. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 2009; 48:89.</a></li><li><a class="nounderline abstract_t">Al-Homaidhi H, Abdel-Haq NM, El-Baba M, Asmar BI. Severe hepatitis associated with oxacillin therapy. South Med J 2002; 95:650.</a></li><li><a class="nounderline abstract_t">Olson SC, Smith S, Weissman SJ, Kronman MP. Adverse Events in Pediatric Patients Receiving Long-Term Outpatient Antimicrobials. J Pediatric Infect Dis Soc 2015; 4:119.</a></li><li><a class="nounderline abstract_t">Murphy JL, Fenn N, Pyle L, et al. Adverse Events in Pediatric Patients Receiving Long-term Oral and Intravenous Antibiotics. Hosp Pediatr 2016; 6:330.</a></li><li><a class="nounderline abstract_t">Ruebner R, Keren R, Coffin S, et al. Complications of central venous catheters used for the treatment of acute hematogenous osteomyelitis. Pediatrics 2006; 117:1210.</a></li><li><a class="nounderline abstract_t">Maraqa NF, Gomez MM, Rathore MH. Outpatient parenteral antimicrobial therapy in osteoarticular infections in children. J Pediatr Orthop 2002; 22:506.</a></li><li><a class="nounderline abstract_t">Bennett OM, Namnyak SS. Acute septic arthritis of the hip joint in infancy and childhood. Clin Orthop Relat Res 1992; :123.</a></li><li><a class="nounderline abstract_t">Yagupsky P. Kingella kingae: from medical rarity to an emerging paediatric pathogen. Lancet Infect Dis 2004; 4:358.</a></li><li><a class="nounderline abstract_t">Arnold SR, Elias D, Buckingham SC, et al. Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureus. J Pediatr Orthop 2006; 26:703.</a></li><li><a class="nounderline abstract_t">Perlman MH, Patzakis MJ, Kumar PJ, Holtom P. The incidence of joint involvement with adjacent osteomyelitis in pediatric patients. J Pediatr Orthop 2000; 20:40.</a></li><li><a class="nounderline abstract_t">Branson J, Vallejo JG, Flores AR, et al. The Contemporary Microbiology and Rates of Concomitant Osteomyelitis in Acute Septic Arthritis. Pediatr Infect Dis J 2017; 36:267.</a></li><li><a class="nounderline abstract_t">Jackson MA, Burry VF, Olson LC. Pyogenic arthritis associated with adjacent osteomyelitis: identification of the sequela-prone child. Pediatr Infect Dis J 1992; 11:9.</a></li><li class="breakAll">Krogstad P. Septic arthritis. In: Current Pediatric Therapy, 18th ed, Burg FD, Ingelfinger JR, Polin RA, Gershon AA (Eds), Saunders, Philadelphia 2006. p.665.</li><li><a class="nounderline abstract_t">Bradley JS. What is the appropriate treatment course for bacterial arthritis in children? Clin Infect Dis 2009; 48:1211.</a></li><li><a class="nounderline abstract_t">Odio CM, Ramirez T, Arias G, et al. Double blind, randomized, placebo-controlled study of dexamethasone therapy for hematogenous septic arthritis in children. Pediatr Infect Dis J 2003; 22:883.</a></li><li><a class="nounderline abstract_t">Harel L, Prais D, Bar-On E, et al. Dexamethasone therapy for septic arthritis in children: results of a randomized double-blind placebo-controlled study. J Pediatr Orthop 2011; 31:211.</a></li><li><a class="nounderline abstract_t">Fogel I, Amir J, Bar-On E, Harel L. Dexamethasone Therapy for Septic Arthritis in Children. Pediatrics 2015; 136:e776.</a></li><li><a class="nounderline abstract_t">Delgado-Noguera MF, Forero Delgadillo JM, Franco AA, et al. Corticosteroids for septic arthritis in children. Cochrane Database Syst Rev 2018; 11:CD012125.</a></li><li><a class="nounderline abstract_t">Ho G Jr, Su EY. Therapy for septic arthritis. JAMA 1982; 247:797.</a></li><li><a class="nounderline abstract_t">WARD J, COHEN AS, BAUER W. The diagnosis and therapy of acute suppurative arthritis. Arthritis Rheum 1960; 3:522.</a></li><li><a class="nounderline abstract_t">Goldenberg DL, Brandt KD, Cathcart ES, Cohen AS. Acute arthritis caused by gram-negative bacilli: a clinical characterization. Medicine (Baltimore) 1974; 53:197.</a></li><li><a class="nounderline abstract_t">Pääkkönen M, Kallio MJ, Kallio PE, Peltola H. Sensitivity of erythrocyte sedimentation rate and C-reactive protein in childhood bone and joint infections. Clin Orthop Relat Res 2010; 468:861.</a></li><li><a class="nounderline abstract_t">Funk SS, Copley LA. Acute Hematogenous Osteomyelitis in Children: Pathogenesis, Diagnosis, and Treatment. Orthop Clin North Am 2017; 48:199.</a></li><li><a class="nounderline abstract_t">Arkader A, Brusalis C, Warner WC Jr, et al. Update in Pediatric Musculoskeletal Infections: When It Is, When It Isn't, and What to Do. J Am Acad Orthop Surg 2016; 24:e112.</a></li><li><a class="nounderline abstract_t">EYRE-BROOK AL. Septic arthritis of the hip and osteomyelitis of the upper end of the femur in infants. J Bone Joint Surg Br 1960; 42-B:11.</a></li><li><a class="nounderline abstract_t">Singer JI. The cause of gait disturbance in 425 pediatric patients. Pediatr Emerg Care 1985; 1:7.</a></li><li><a class="nounderline abstract_t">Bos CF, Mol LJ, Obermann WR, Tjin a Ton ER. Late sequelae of neonatal septic arthritis of the shoulder. J Bone Joint Surg Br 1998; 80:645.</a></li><li><a class="nounderline abstract_t">Howard-Jones AR, Isaacs D, Gibbons PJ. Twelve-month outcome following septic arthritis in children. J Pediatr Orthop B 2013; 22:486.</a></li><li><a class="nounderline abstract_t">Yuan HC, Wu KG, Chen CJ, et al. Characteristics and outcome of septic arthritis in children. J Microbiol Immunol Infect 2006; 39:342.</a></li><li><a class="nounderline abstract_t">Sukswai P, Kovitvanitcha D, Thumkunanon V, et al. Acute hematogenous osteomyelitis and septic arthritis in children: clinical characteristics and outcomes study. J Med Assoc Thai 2011; 94 Suppl 3:S209.</a></li><li><a class="nounderline abstract_t">Betz RR, Cooperman DR, Wopperer JM, et al. Late sequelae of septic arthritis of the hip in infancy and childhood. J Pediatr Orthop 1990; 10:365.</a></li><li class="breakAll">Swami SK, Eppes SC. Bone and joint infections. In: Comprehensive Pediatric Hospital Medicine, 2nd ed, Zaoutis LB, Chiang WV (Eds), McGraw Hill Education, New York 2018. p.566.</li><li><a class="nounderline abstract_t">Li Y, Zhou Q, Liu Y, et al. Delayed treatment of septic arthritis in the neonate: A review of 52 cases. Medicine (Baltimore) 2016; 95:e5682.</a></li><li><a class="nounderline abstract_t">Morrey BF, Bianco AJ, Rhodes KH. Suppurative arthritis of the hip in children. J Bone Joint Surg Am 1976; 58:388.</a></li><li><a class="nounderline abstract_t">Lunseth PA, Heiple KG. Prognosis in septic arthritis of the hip in children. Clin Orthop Relat Res 1979; :81.</a></li><li><a class="nounderline abstract_t">Goldenberg DL, Cohen AS. Acute infectious arthritis. A review of patients with nongonococcal joint infections (with emphasis on therapy and prognosis). Am J Med 1976; 60:369.</a></li><li><a class="nounderline abstract_t">Newman JH. Review of septic arthritis throughout the antibiotic era. Ann Rheum Dis 1976; 35:198.</a></li><li><a class="nounderline abstract_t">Ernat J, Riccio AI, Fitzpatrick K, et al. Osteomyelitis is Commonly Associated With Septic Arthritis of the Shoulder in Children. J Pediatr Orthop 2015.</a></li></ol></div><div id="topicVersionRevision">Topic 6033 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12787520" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Septic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12787520" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Septic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12787520" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Septic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12783993" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A clinical practice guideline for treatment of septic arthritis in children: efficacy in improving process of care and effect on outcome of septic arthritis of the hip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3778543" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bacterial arthritis. A staphylococcal proteoglycan-releasing factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2929280" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antibiotic treatment insufficient for established septic arthritis. Staphylococcus aureus experiments in rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7844133" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evaluation of treatment modalities for septic arthritis with histological grading and analysis of levels of uronic acid, neutral protease, and interleukin-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28708801" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bone and Joint Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28708801" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bone and Joint Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18525361" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Septic arthritis: current diagnostic and therapeutic algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1101133" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Septic arthritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3489736" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Management of septic arthritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1115748" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of septic arthritis: comparison of needle aspiration and surgery as initial modes of joint drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1262374" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Lavage of septic joints in rabbits: effects of chondrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12463664" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Septic arthritis of the shoulder in children in Malawi. A randomised, prospective study of aspiration versus arthrotomy and washout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2924466" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Arthroscopy in acute septic knees. Management in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945678" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Arthroscopic Versus Open Treatment for Acute Septic Arthritis of the Knee in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19308583" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment of early septic arthritis of the hip in children: comparison of results of open arthrotomy versus arthroscopic drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26398437" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Arthroscopic Treatment of Septic Arthritis in Very Young Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19323633" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prospective, randomized trial of 10 days versus 30 days of antimicrobial treatment, including a short-term course of parenteral therapy, for childhood septic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3542355" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A comparison of medical drainage (needle aspiration) and surgical drainage (arthrotomy or arthroscopy) in the initial treatment of infected joints.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3833965" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Childhood hip sepsis: improving the yield of good results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6630490" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Septic arthritis of the hip in children: poor results after late and inadequate treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20104170" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A clinical analysis of shoulder and hip joint infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12463665" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Arthroscopic washout of the shoulder for septic arthritis in infants. A new technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12567149" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Arthroscopic treatment of septic arthritis of the hip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16904592" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Arthroscopic treatment of septic arthritis of the hip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8370777" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Treatment of septic arthritis of the hip by arthroscopic lavage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20220532" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pediatric septic hip with or without arthrotomy: retrospective analysis of 62 consecutive nonneonatal culture-positive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15105721" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treatment of septic arthritis of the hip joint by repeated ultrasound-guided aspirations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21307737" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Percutaneous aspiration irrigation drainage technique in the management of septic arthritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27455444" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Epidemiology and Management of Acute, Uncomplicated Septic Arthritis and Osteomyelitis: Spanish Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26725213" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Arthroscopy for hip septic arthritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3733835" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Acute septic arthritis in infancy and childhood. 10 years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9156391" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Septic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3883171" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Bacterial arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19721035" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The management of septic arthritis in children: systematic review of the English language literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3492327" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Septic arthritis and osteomyelitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4398136" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Ampicillin and kanamycin concentrations in joint fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The penetration of penicillin into joint fluid following intramuscular administration</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4403468" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The bacterial etiology and antibiotic management of septic arthritis in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5429181" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Penetration of clindamycin into synovial fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5539915" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Antibiotic concentrations in septic joint effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289450" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6993944" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Osteomyelitis: the past decade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20864323" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : [Coagulase-negative staphylococcal osteomyelitis in preterm infants: a proposal for a diagnostic procedure].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12828160" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Primary osteomyelitis and suppurative arthritis caused by coagulase-negative staphylococci in a preterm neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9269165" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Decline of bone and joint infections attributable to haemophilus influenzae type b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10069312" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Etiology of septic arthritis in children: an update for the 1990s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19820424" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : USA300 is the predominant genotype causing Staphylococcus aureus septic arthritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17984803" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Experience with linezolid therapy in children with osteoarticular infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22903951" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26766937" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Ceftaroline Fosamil Use in 2 Pediatric Patients With Invasive Methicillin-Resistant Staphylococcus aureus Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22011265" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clindamycin vs. first-generation cephalosporins for acute osteoarticular infections of childhood--a prospective quasi-randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16024681" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Outbreak of osteomyelitis/septic arthritis caused by Kingella kingae among child care center attendees.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22252209" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Antibiotic susceptibility of Kingella kingae isolates from children with skeletal system infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21321033" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Kingella kingae: an emerging pathogen in young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20182400" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Invasive pediatric Kingella kingae Infections: a nationwide collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23856785" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Unusually severe cases of Kingella kingae osteoarticular infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26625369" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Age-Dependent Carriage of Kingella kingae in Young Children and Turnover of Colonizing Strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9832572" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pediatric pneumococcal bone and joint infections. The Pediatric Multicenter Pneumococcal Surveillance Study Group (PMPSSG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28723870" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Osteoarticular Infections Caused by Streptococcus pneumoniae in Children in the Post-Pneumococcal Conjugate Vaccine Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26362744" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Septic arthritis in immunocompetent and immunosuppressed hosts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3498362" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Septic arthritis in childhood. A 13-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3540888" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pyogenic arthritis in infants and children: a review of 95 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/313236" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Septic arthritis in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19700997" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A comparison of early versus late conversion from intravenous to oral therapy in the treatment of septic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10608634" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Oral antibiotic therapy of bacterial arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11961446" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Short-term intravenous antibiotic treatment of acute hematogenous bone and joint infection in children: a prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10641687" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A shortened course of parenteral antibiotic therapy in the management of acute septic arthritis of the hip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/632997" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Oral antibiotic therapy for skeletal infections of children. II. Therapy of osteomyelitis and suppurative arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7367131" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Oral antibiotic therapy of skeletal infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22966033" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Acute bacterial osteoarticular infections: eight-year analysis of C-reactive protein for oral step-down therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25929777" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The Use of C-reactive Protein as a Guide for Transitioning to Oral Antibiotics in Pediatric Osteoarticular Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2495877" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Neonatal group B streptococcal osteomyelitis and suppurative arthritis. Outpatient therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/940031" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Subtherapeutic dicloxacillin levels in a neonate: possible mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7130382" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Benefits and risks of sequential parenteral--oral cephalosporin therapy for suppurative bone and joint infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/430319" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : High-dose oral dicloxacillin treatment of acute staphylococcal osteomyelitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12867833" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19271782" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12081223" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Severe hepatitis associated with oxacillin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26407410" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Adverse Events in Pediatric Patients Receiving Long-Term Outpatient Antimicrobials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27220835" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Adverse Events in Pediatric Patients Receiving Long-term Oral and Intravenous Antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16585317" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Complications of central venous catheters used for the treatment of acute hematogenous osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12131449" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Outpatient parenteral antimicrobial therapy in osteoarticular infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1499198" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Acute septic arthritis of the hip joint in infancy and childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15172344" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Kingella kingae: from medical rarity to an emerging paediatric pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17065930" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10641686" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The incidence of joint involvement with adjacent osteomyelitis in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27870814" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The Contemporary Microbiology and Rates of Concomitant Osteomyelitis in Acute Septic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1549419" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Pyogenic arthritis associated with adjacent osteomyelitis: identification of the sequela-prone child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1549419" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pyogenic arthritis associated with adjacent osteomyelitis: identification of the sequela-prone child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19323629" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : What is the appropriate treatment course for bacterial arthritis in children?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14551489" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Double blind, randomized, placebo-controlled study of dexamethasone therapy for hematogenous septic arthritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21307717" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Dexamethasone therapy for septic arthritis in children: results of a randomized double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26347429" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Dexamethasone Therapy for Septic Arthritis in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30480764" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Corticosteroids for septic arthritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7057556" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Therapy for septic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13783106" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The diagnosis and therapy of acute suppurative arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4207743" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Acute arthritis caused by gram-negative bacilli: a clinical characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19533263" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Sensitivity of erythrocyte sedimentation rate and C-reactive protein in childhood bone and joint infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28336042" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Acute Hematogenous Osteomyelitis in Children: Pathogenesis, Diagnosis, and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27466008" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Update in Pediatric Musculoskeletal Infections: When It Is, When It Isn't, and What to Do.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13849742" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Septic arthritis of the hip and osteomyelitis of the upper end of the femur in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3843430" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The cause of gait disturbance in 425 pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9699829" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Late sequelae of neonatal septic arthritis of the shoulder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23531603" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Twelve-month outcome following septic arthritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16926982" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Characteristics and outcome of septic arthritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22043778" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Acute hematogenous osteomyelitis and septic arthritis in children: clinical characteristics and outcomes study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2355081" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Late sequelae of septic arthritis of the hip in infancy and childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2355081" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Late sequelae of septic arthritis of the hip in infancy and childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28002339" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Delayed treatment of septic arthritis in the neonate: A review of 52 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1262373" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Suppurative arthritis of the hip in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/455855" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Prognosis in septic arthritis of the hip in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/769545" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Acute infectious arthritis. A review of patients with nongonococcal joint infections (with emphasis on therapy and prognosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/984899" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Review of septic arthritis throughout the antibiotic era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26691242" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Osteomyelitis is Commonly Associated With Septic Arthritis of the Shoulder in Children.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
